{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:44:53Z","timestamp":1776797093426,"version":"3.51.2"},"publisher-location":"Cham","reference-count":191,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031963636","type":"print"},{"value":"9783031963643","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-96364-3_3","type":"book-chapter","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:06:18Z","timestamp":1759737978000},"page":"63-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unlocking the Potential of High-Quality Dopamine Transporter Pharmacological Data: Advancing Robust Machine Learning-Based QSAR Modeling"],"prefix":"10.1007","author":[{"given":"Kuo Hao","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Joon","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Precious","family":"Oyinloye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"5","key":"3_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00424-003-1064-5","volume":"447","author":"NH Chen","year":"2004","unstructured":"Chen NH, Reith ME, Quick MW (2004) Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch 447(5):519\u2013531. https:\/\/doi.org\/10.1007\/s00424-003-1064-5. From NLM Medline","journal-title":"Pflugers Arch"},{"issue":"5","key":"3_CR2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1124\/mol.106.026120","volume":"70","author":"T Beuming","year":"2006","unstructured":"Beuming T, Shi L, Javitch JA, Weinstein H (2006) A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter\/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol Pharmacol 70(5):1630\u20131642. https:\/\/doi.org\/10.1124\/mol.106.026120","journal-title":"Mol Pharmacol"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"12 16 11\u201312 16","DOI":"10.1002\/cpph.32","volume":"79","author":"S Aggarwal","year":"2017","unstructured":"Aggarwal S, Mortensen OV (2017) Overview of monoamine transporters. Curr Protoc Pharmacol 79:12 16 11\u201312 16 17. https:\/\/doi.org\/10.1002\/cpph.32. From NLM Medline","journal-title":"Curr Protoc Pharmacol"},{"key":"3_CR4","doi-asserted-by":"publisher","first-page":"9730467","DOI":"10.1155\/2016\/9730467","volume":"2016","author":"H Juarez Olguin","year":"2016","unstructured":"Juarez Olguin H, Calderon Guzman D, Hernandez Garcia E, Barragan Mejia G (2016) The role of Dopamine and its dysfunction as a consequence of oxidative stress. Oxidative Med Cell Longev 2016:9730467. https:\/\/doi.org\/10.1155\/2016\/9730467. From NLM Medline","journal-title":"Oxidative Med Cell Longev"},{"issue":"22","key":"3_CR5","doi-asserted-by":"publisher","first-page":"13992","DOI":"10.1074\/jbc.M114.625343","volume":"290","author":"S Stolzenberg","year":"2015","unstructured":"Stolzenberg S, Quick M, Zhao C, Gotfryd K, Khelashvili G, Gether U, Loland CJ, Javitch JA, Noskov S, Weinstein H et al (2015) Mechanism of the association between Na+ binding and conformations at the intracellular gate in neurotransmitter:sodium symporters. J Biol Chem 290(22):13992\u201314003. https:\/\/doi.org\/10.1074\/jbc.M114.625343","journal-title":"J Biol Chem"},{"issue":"37","key":"3_CR6","doi-asserted-by":"publisher","first-page":"25764","DOI":"10.1074\/jbc.M114.574269","volume":"289","author":"L Borre","year":"2014","unstructured":"Borre L, Andreassen TF, Shi L, Weinstein H, Gether U (2014) The second sodium site in the dopamine transporter controls cation permeation and is regulated by chloride. J Biol Chem 289(37):25764\u201325773. https:\/\/doi.org\/10.1074\/jbc.M114.574269","journal-title":"J Biol Chem"},{"key":"3_CR7","first-page":"993\u2013998","volume":"56(4)","author":"EH Cook Jr","year":"1995","unstructured":"Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL (1995) Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56(4):993\u2013998. From NLM Medline","journal-title":"Am J Hum Genet"},{"issue":"6","key":"3_CR8","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1086\/302132","volume":"63","author":"ID Waldman","year":"1998","unstructured":"Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL, Cleveland HH, Sanders ML, Gard JM, Stever C (1998) Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 63(6):1767\u20131776. https:\/\/doi.org\/10.1086\/302132. From NLM Medline","journal-title":"Am J Hum Genet"},{"issue":"2","key":"3_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/sj.mp.4001764","volume":"11","author":"TA Greenwood","year":"2006","unstructured":"Greenwood TA, Schork NJ, Eskin E, Kelsoe JR (2006) Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples. Mol Psychiatry 11(2):125\u2013133, 115. https:\/\/doi.org\/10.1038\/sj.mp.4001764. From NLM Medline","journal-title":"Mol Psychiatry"},{"issue":"5","key":"3_CR10","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/mp.2017.16","volume":"22","author":"AH Ashok","year":"2017","unstructured":"Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH, Howes OD (2017) The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 22(5):666\u2013679. https:\/\/doi.org\/10.1038\/mp.2017.16. From NLM Medline","journal-title":"Mol Psychiatry"},{"issue":"1","key":"3_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41398-022-02080-z","volume":"12","author":"T Tamura","year":"2022","unstructured":"Tamura T, Sugihara G, Okita K, Mukai Y, Matsuda H, Shiwaku H, Takagi S, Daisaki H, Tateishi U, Takahashi H (2022) Dopamine dysfunction in depression: application of texture analysis to dopamine transporter single-photon emission computed tomography imaging. Transl Psychiatry 12(1):309. https:\/\/doi.org\/10.1038\/s41398-022-02080-z. From NLM Medline","journal-title":"Transl Psychiatry"},{"key":"3_CR12","first-page":"112","volume":"128","author":"AT McLellan","year":"2017","unstructured":"McLellan AT (2017) Substance misuse and substance use disorders: why do they matter in healthcare? Trans Am Clin Climatol Assoc 128:112\u2013130. From NLM Medline","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"3_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/SAR.S337338","volume":"13","author":"EKC Schwartz","year":"2022","unstructured":"Schwartz EKC, Wolkowicz NR, De Aquino JP, MacLean RR, Sofuoglu M (2022) Cocaine Use Disorder (CUD): current clinical perspectives. Subst Abus Rehabil 13:25\u201346. https:\/\/doi.org\/10.2147\/SAR.S337338. From NLM PubMed-not-MEDLINE","journal-title":"Subst Abus Rehabil"},{"key":"3_CR14","unstructured":"Abuse, N. I. o. D. Drug overdose death rates (2023). https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates. Accessed 16 Dec 2023"},{"issue":"6566","key":"3_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/379606a0","volume":"379","author":"B Giros","year":"1996","unstructured":"Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379(6566):606\u2013612. https:\/\/doi.org\/10.1038\/379606a0. From NLM Medline","journal-title":"Nature"},{"issue":"24","key":"3_CR16","doi-asserted-by":"publisher","first-page":"9333","DOI":"10.1073\/pnas.0600905103","volume":"103","author":"R Chen","year":"2006","unstructured":"Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S, Quan N, Stephens RL, Hill ER, Nottoli T et al (2006) Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci USA 103(24):9333\u20139338. https:\/\/doi.org\/10.1073\/pnas.0600905103. From NLM Medline","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/med.10014","volume":"22","author":"AH Newman","year":"2002","unstructured":"Newman AH, Kulkarni S (2002) Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic--a focus on analogues of benztropine and rimcazole. Med Res Rev 22(5):429\u2013464. https:\/\/doi.org\/10.1002\/med.10014. From NLM Medline","journal-title":"Med Res Rev"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/7355_2008_027","volume":"4","author":"AH Newman","year":"2009","unstructured":"Newman AH, Katz JL (2009) Atypical Dopamine uptake inhibitors that provide clues about Cocaine\u2019s mechanism at the Dopamine transporter. Top Med Chem Ser 4:95\u2013129. https:\/\/doi.org\/10.1007\/7355_2008_027","journal-title":"Top Med Chem Ser"},{"issue":"3","key":"3_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1124\/mol.107.039800","volume":"73","author":"CJ Loland","year":"2008","unstructured":"Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, Sitte HH, Newman AH, Katz JL, Gether U (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73(3):813\u2013823. https:\/\/doi.org\/10.1124\/mol.107.039800. From NLM Medline","journal-title":"Mol Pharmacol"},{"key":"3_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.12.005","volume":"147","author":"ME Reith","year":"2015","unstructured":"Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL (2015) Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147:1\u201319. https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.12.005. From NLM Medline","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"3_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025790","volume":"6","author":"KC Schmitt","year":"2011","unstructured":"Schmitt KC, Reith ME (2011) The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One 6(10):e25790. https:\/\/doi.org\/10.1371\/journal.pone.0025790. From NLM Medline","journal-title":"PLoS One"},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"1150355","DOI":"10.3389\/fphys.2023.1150355","volume":"14","author":"B Nepal","year":"2023","unstructured":"Nepal B, Das S, Reith ME, Kortagere S (2023) Overview of the structure and function of the dopamine transporter and its protein interactions. Front Physiol 14:1150355. https:\/\/doi.org\/10.3389\/fphys.2023.1150355. From NLM PubMed-not-MEDLINE","journal-title":"Front Physiol"},{"issue":"8","key":"3_CR23","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1021\/acschemneuro.7b00094","volume":"8","author":"AM Abramyan","year":"2017","unstructured":"Abramyan AM, Stolzenberg S, Li Z, Loland CJ, Noe F, Shi L (2017) The isomeric preference of an atypical Dopamine transporter inhibitor contributes to its selection of the transporter conformation. ACS Chem Neurosci 8(8):1735\u20131746. https:\/\/doi.org\/10.1021\/acschemneuro.7b00094. From NLM Medline","journal-title":"ACS Chem Neurosci"},{"issue":"24","key":"3_CR24","doi-asserted-by":"publisher","first-page":"10172","DOI":"10.1021\/acs.jmedchem.7b01454","volume":"60","author":"MF Zou","year":"2017","unstructured":"Zou MF, Cao J, Abramyan AM, Kopajtic T, Zanettini C, Guthrie DA, Rais R, Slusher BS, Shi L, Loland CJ et al (2017) Structure-activity relationship studies on a series of 3alpha-[Bis(4-fluorophenyl)methoxy]tropanes and 3alpha-[Bis(4-fluorophenyl)methylamino]tropanes as novel atypical Dopamine transporter (DAT) inhibitors for the treatment of cocaine use disorders. J Med Chem 60(24):10172\u201310187. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01454. From NLM Medline","journal-title":"J Med Chem"},{"issue":"1","key":"3_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bcp.2007.08.007","volume":"75","author":"RB Rothman","year":"2008","unstructured":"Rothman RB, Baumann MH, Prisinzano TE, Newman AH (2008) Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol 75(1):2\u201316. https:\/\/doi.org\/10.1016\/j.bcp.2007.08.007. From NLM Medline","journal-title":"Biochem Pharmacol"},{"issue":"24","key":"3_CR26","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.1021\/jm040117o","volume":"47","author":"J Zhou","year":"2004","unstructured":"Zhou J, He R, Johnson KM, Ye Y, Kozikowski AP (2004) Piperidine-based nocaine\/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization. J Med Chem 47(24):5821\u20135824. https:\/\/doi.org\/10.1021\/jm040117o. From NLM Medline","journal-title":"J Med Chem"},{"issue":"5","key":"3_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.biopsych.2012.03.022","volume":"72","author":"CJ Loland","year":"2012","unstructured":"Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, Kopajtic T, Shi L, Katz JL, Tanda G et al (2012) R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry 72(5):405\u2013413. https:\/\/doi.org\/10.1016\/j.biopsych.2012.03.022. From NLM Medline","journal-title":"Biol Psychiatry"},{"issue":"3","key":"3_CR28","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1021\/jm401754x","volume":"57","author":"OM Okunola-Bakare","year":"2014","unstructured":"Okunola-Bakare OM, Cao J, Kopajtic T, Katz JL, Loland CJ, Shi L, Newman AH (2014) Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues. J Med Chem 57(3):1000\u20131013. https:\/\/doi.org\/10.1021\/jm401754x","journal-title":"J Med Chem"},{"issue":"1","key":"3_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1146\/annurev-pharmtox-030220-124205","volume":"61","author":"AH Newman","year":"2021","unstructured":"Newman AH, Ku T, Jordan CJ, Bonifazi A, Xi ZX (2021) New drugs, old targets: tweaking the Dopamine system to treat psychostimulant use disorders. Annu Rev Pharmacol Toxicol 61(1):609\u2013628. https:\/\/doi.org\/10.1146\/annurev-pharmtox-030220-124205. (acccessed 2023\/12\/16). From NLM Medline","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"30","key":"3_CR30","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.2174\/092986708786848523","volume":"15","author":"J Pratuangdejkul","year":"2008","unstructured":"Pratuangdejkul J, Schneider B, Launay JM, Kellermann O, Manivet P (2008) Computational approaches for the study of serotonin and its membrane transporter SERT: implications for drug design in neurological sciences. Curr Med Chem 15(30):3214\u20133227. https:\/\/doi.org\/10.2174\/092986708786848523. From NLM Medline","journal-title":"Curr Med Chem"},{"issue":"9","key":"3_CR31","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1021\/cn500133b","volume":"5","author":"TL Nolan","year":"2014","unstructured":"Nolan TL, Geffert LM, Kolber BJ, Madura JD, Surratt CK (2014) Discovery of novel-scaffold monoamine transporter ligands via in silico screening with the S1 pocket of the serotonin transporter. ACS Chem Neurosci 5(9):784\u2013792. https:\/\/doi.org\/10.1021\/cn500133b. From NLM Medline","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"3_CR32","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1021\/ci200280m","volume":"51","author":"S Manepalli","year":"2011","unstructured":"Manepalli S, Geffert LM, Surratt CK, Madura JD (2011) Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore. J Chem Inf Model 51(9):2417\u20132426. https:\/\/doi.org\/10.1021\/ci200280m. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"2","key":"3_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3109\/09687688.2012.710341","volume":"30","author":"KJ Simmons","year":"2013","unstructured":"Simmons KJ, Gotfryd K, Billesbolle CB, Loland CJ, Gether U, Fishwick CW, Johnson AP (2013) A virtual high-throughput screening approach to the discovery of novel inhibitors of the bacterial leucine transporter, LeuT. Mol Membr Biol 30(2):184\u2013194. https:\/\/doi.org\/10.3109\/09687688.2012.710341. From NLM Medline","journal-title":"Mol Membr Biol"},{"issue":"38","key":"3_CR34","doi-asserted-by":"publisher","first-page":"15810","DOI":"10.1073\/pnas.1106030108","volume":"108","author":"A Schlessinger","year":"2011","unstructured":"Schlessinger A, Geier E, Fan H, Irwin JJ, Shoichet BK, Giacomini KM, Sali A (2011) Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci USA 108(38):15810\u201315815. https:\/\/doi.org\/10.1073\/pnas.1106030108. From NLM Medline","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"3_CR35","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1021\/acschemneuro.9b00262","volume":"10","author":"S Aggarwal","year":"2019","unstructured":"Aggarwal S, Liu X, Rice C, Menell P, Clark PJ, Paparoidamis N, Xiao YC, Salvino JM, Fontana ACK, Espana RA et al (2019) Identification of a novel allosteric modulator of the human Dopamine transporter. ACS Chem Neurosci 10(8):3718\u20133730. https:\/\/doi.org\/10.1021\/acschemneuro.9b00262. From NLM Medline","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"3_CR36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/prot.21598","volume":"70","author":"M Indarte","year":"2008","unstructured":"Indarte M, Madura JD, Surratt CK (2008) Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template. Proteins 70(3):1033\u20131046. https:\/\/doi.org\/10.1002\/prot.21598. From NLM Medline","journal-title":"Proteins"},{"key":"3_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106324","volume":"181","author":"D Vemula","year":"2023","unstructured":"Vemula D, Jayasurya P, Sushmitha V, Kumar YN, Bhandari V (2023) CADD, AI and ML in drug discovery: a comprehensive review. Eur J Pharm Sci 181:106324. https:\/\/doi.org\/10.1016\/j.ejps.2022.106324. From NLM Medline","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"3_CR38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2174\/1568026611313090003","volume":"13","author":"A Voet","year":"2013","unstructured":"Voet A, Banwell EF, Sahu KK, Heddle JG, Zhang KY (2013) Protein interface pharmacophore mapping tools for small molecule protein: protein interaction inhibitor discovery. Curr Top Med Chem 13(9):989\u20131001. https:\/\/doi.org\/10.2174\/1568026611313090003. From NLM Medline","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"3_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/157340607780059521","volume":"3","author":"SA Khedkar","year":"2007","unstructured":"Khedkar SA, Malde AK, Coutinho EC, Srivastava S (2007) Pharmacophore modeling in drug discovery and development: an overview. Med Chem 3(2):187\u2013197. https:\/\/doi.org\/10.2174\/157340607780059521. From NLM Medline","journal-title":"Med Chem"},{"issue":"15","key":"3_CR40","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1016\/j.bmc.2007.05.015","volume":"15","author":"HS Christensen","year":"2007","unstructured":"Christensen HS, Boye SV, Thinggaard J, Sinning S, Wiborg O, Schiott B, Bols M (2007) QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter. Bioorg Med Chem 15(15):5262\u20135274. https:\/\/doi.org\/10.1016\/j.bmc.2007.05.015. From NLM Medline","journal-title":"Bioorg Med Chem"},{"issue":"4824","key":"3_CR41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/194178b0","volume":"194","author":"C Hansch","year":"1962","unstructured":"Hansch C, Maloney PP, Fujita T (1962) Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients. Nature 194(4824):178. https:\/\/doi.org\/10.1038\/194178b0","journal-title":"Nature"},{"issue":"1","key":"3_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1021\/cr0780210","volume":"109","author":"RP Verma","year":"2009","unstructured":"Verma RP, Hansch C (2009) Camptothecins: a SAR\/QSAR study. Chem Rev 109(1):213\u2013235. https:\/\/doi.org\/10.1021\/cr0780210. From NLM Medline","journal-title":"Chem Rev"},{"issue":"45","key":"3_CR43","doi-asserted-by":"publisher","first-page":"11122","DOI":"10.1021\/acs.jpclett.1c03133","volume":"12","author":"K Gao","year":"2021","unstructured":"Gao K, Chen D, Robison AJ, Wei GW (2021) Proteome-informed machine learning studies of cocaine addiction. J Phys Chem Lett 12(45):11122\u201311134. https:\/\/doi.org\/10.1021\/acs.jpclett.1c03133. From NLM Medline","journal-title":"J Phys Chem Lett"},{"issue":"8","key":"3_CR44","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.drudis.2016.06.013","volume":"21","author":"Danishuddin","year":"2016","unstructured":"Danishuddin, Khan AU (2016) Descriptors and their selection methods in QSAR analysis: paradigm for drug design. Drug Discov Today 21(8):1291\u20131302. https:\/\/doi.org\/10.1016\/j.drudis.2016.06.013. From NLM Medline","journal-title":"Drug Discov Today"},{"issue":"9","key":"3_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103052","volume":"24","author":"J Mao","year":"2021","unstructured":"Mao J, Akhtar J, Zhang X, Sun L, Guan S, Li X, Chen G, Liu J, Jeon HN, Kim MS et al (2021) Comprehensive strategies of machine-learning-based quantitative structure-activity relationship models. iScience 24(9):103052. https:\/\/doi.org\/10.1016\/j.isci.2021.103052. From NLM PubMed-not-MEDLINE","journal-title":"iScience"},{"issue":"7","key":"3_CR46","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1021\/ci800038f","volume":"48","author":"H Hong","year":"2008","unstructured":"Hong H, Xie Q, Ge W, Qian F, Fang H, Shi L, Su Z, Perkins R, Tong W (2008) Mold(2), molecular descriptors from 2D structures for chemoinformatics and toxicoinformatics. J Chem Inf Model 48(7):1337\u20131344. https:\/\/doi.org\/10.1021\/ci800038f. From NLM Medline","journal-title":"J Chem Inf Model"},{"key":"3_CR47","first-page":"237\u2013248, Articl","volume":"56(2)","author":"A Mauri","year":"2006","unstructured":"Mauri A, Consonni V, Pavan M, Todeschini R (2006) Dragon software: an easy approach to molecular descriptor calculations. Match-Commun Math Co 56(2):237\u2013248, Article. Scopus","journal-title":"Match-Commun Math Co"},{"issue":"3\u20134","key":"3_CR48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/1062936X.2012.657677","volume":"23","author":"YS Cho","year":"2012","unstructured":"Cho YS, No KT, Cho KH (2012) yaInChI: modified InChI string scheme for line notation of chemical structures. SAR QSAR Environ Res 23(3\u20134):237\u2013255. https:\/\/doi.org\/10.1080\/1062936X.2012.657677. From NLM Medline","journal-title":"SAR QSAR Environ Res"},{"issue":"5","key":"3_CR49","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bmc.2005.10.010","volume":"14","author":"SY Choi","year":"2006","unstructured":"Choi SY, Shin JH, Ryu CK, Nam KY, No KT, Park Choo HY (2006) The development of 3D-QSAR study and recursive partitioning of heterocyclic quinone derivatives with antifungal activity. Bioorg Med Chem 14(5):1608\u20131617. https:\/\/doi.org\/10.1016\/j.bmc.2005.10.010. From NLM Medline","journal-title":"Bioorg Med Chem"},{"key":"3_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2019.107515","volume":"96","author":"D Hayakawa","year":"2020","unstructured":"Hayakawa D, Sawada N, Watanabe Y, Gouda H (2020) A molecular interaction field describing nonconventional intermolecular interactions and its application to protein-ligand interaction prediction. J Mol Graph Model 96:107515. https:\/\/doi.org\/10.1016\/j.jmgm.2019.107515. From NLM Medline","journal-title":"J Mol Graph Model"},{"issue":"22","key":"3_CR51","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1021\/jm990472s","volume":"43","author":"BT Hoffman","year":"2000","unstructured":"Hoffman BT, Kopajtic T, Katz JL, Newman AH (2000) 2D QSAR modeling and preliminary database searching for dopamine transporter inhibitors using genetic algorithm variable selection of Molconn Z descriptors. J Med Chem 43(22):4151\u20134159. https:\/\/doi.org\/10.1021\/jm990472s. From NLM Medline","journal-title":"J Med Chem"},{"issue":"19","key":"3_CR52","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1021\/jm0102093","volume":"45","author":"SS Kulkarni","year":"2002","unstructured":"Kulkarni SS, Newman AH, Houlihan WJ (2002) Three-dimensional quantitative structure-activity relationships of mazindol analogues at the dopamine transporter. J Med Chem 45(19):4119\u20134127. https:\/\/doi.org\/10.1021\/jm0102093. From NLM Medline","journal-title":"J Med Chem"},{"issue":"8","key":"3_CR53","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1021\/acs.jcim.2c00256","volume":"62","author":"X Zhang","year":"2022","unstructured":"Zhang X, Mao J, Wei M, Qi Y, Zhang JZH (2022) HergSPred: accurate classification of hERG blockers\/nonblockers with machine-learning models. J Chem Inf Model 62(8):1830\u20131839. https:\/\/doi.org\/10.1021\/acs.jcim.2c00256. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"22","key":"3_CR54","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1021\/acs.jcim.2c01422","volume":"62","author":"TA Soares","year":"2022","unstructured":"Soares TA, Nunes-Alves A, Mazzolari A, Ruggiu F, Wei GW, Merz K (2022) The (Re)-evolution of Quantitative Structure-Activity Relationship (QSAR) studies propelled by the surge of machine learning methods. J Chem Inf Model 62(22):5317\u20135320. https:\/\/doi.org\/10.1021\/acs.jcim.2c01422. From NLM Medline","journal-title":"J Chem Inf Model"},{"key":"3_CR55","doi-asserted-by":"publisher","first-page":"78737","DOI":"10.1109\/access.2020.2990375","volume":"8","author":"SA Alsenan","year":"2020","unstructured":"Alsenan SA, Al-Turaiki IM, Hafez AM (2020) Feature extraction methods in quantitative structure\u2013activity relationship modeling: a comparative study. IEEE Access 8:78737\u201378752. https:\/\/doi.org\/10.1109\/access.2020.2990375","journal-title":"IEEE Access"},{"key":"3_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-023-00832-0","volume":"23","author":"A Tropsha","year":"2023","unstructured":"Tropsha A, Isayev O, Varnek A, Schneider G, Cherkasov A (2023) Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR. Nat Rev Drug Discov 23:141. https:\/\/doi.org\/10.1038\/s41573-023-00832-0. From NLM Publisher","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3_CR57","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1021\/ci049965i","volume":"44","author":"XJ Yao","year":"2004","unstructured":"Yao XJ, Panaye A, Doucet JP, Zhang RS, Chen HF, Liu MC, Hu ZD, Fan BT (2004) Comparative study of QSAR\/QSPR correlations using support vector machines, radial basis function neural networks, and multiple linear regression. J Chem Inf Comput Sci 44(4):1257\u20131266. https:\/\/doi.org\/10.1021\/ci049965i. From NLM Medline","journal-title":"J Chem Inf Comput Sci"},{"issue":"2","key":"3_CR58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1021\/ci500747n","volume":"55","author":"J Ma","year":"2015","unstructured":"Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V (2015) Deep neural nets as a method for quantitative structure-activity relationships. J Chem Inf Model 55(2):263\u2013274. https:\/\/doi.org\/10.1021\/ci500747n. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"12","key":"3_CR59","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1021\/acs.jcim.6b00591","volume":"56","author":"RP Sheridan","year":"2016","unstructured":"Sheridan RP, Wang WM, Liaw A, Ma J, Gifford EM (2016) Extreme gradient boosting as a method for quantitative structure-activity relationships. J Chem Inf Model 56(12):2353\u20132360. https:\/\/doi.org\/10.1021\/acs.jcim.6b00591. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"6","key":"3_CR60","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1021\/ci034160g","volume":"43","author":"V Svetnik","year":"2003","unstructured":"Svetnik V, Liaw A, Tong C, Culberson JC, Sheridan RP, Feuston BP (2003) Random forest: a classification and regression tool for compound classification and QSAR modeling. J Chem Inf Comput Sci 43(6):1947\u20131958. https:\/\/doi.org\/10.1021\/ci034160g. From NLM PubMed-not-MEDLINE","journal-title":"J Chem Inf Comput Sci"},{"key":"3_CR61","doi-asserted-by":"publisher","first-page":"D1100\u20131107","DOI":"10.1093\/nar\/gkr777","volume":"40(Database iss","author":"A Gaulton","year":"2012","unstructured":"Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B et al (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40(Database issue):D1100\u20131107. https:\/\/doi.org\/10.1093\/nar\/gkr777. From NLM Medline","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"3_CR62","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46(D1):D1074\u2013D1082. https:\/\/doi.org\/10.1093\/nar\/gkx1037. From NLM Medline","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"3_CR63","doi-asserted-by":"publisher","first-page":"D1045","DOI":"10.1093\/nar\/gkv1072","volume":"44","author":"MK Gilson","year":"2016","unstructured":"Gilson MK, Liu T, Baitaluk M, Nicola G, Hwang L, Chong J (2016) BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res 44(D1):D1045\u2013D1053. https:\/\/doi.org\/10.1093\/nar\/gkv1072. From NLM Medline","journal-title":"Nucleic Acids Res"},{"key":"3_CR64","doi-asserted-by":"publisher","first-page":"D198\u2013201","DOI":"10.1093\/nar\/gkl999","volume":"35(Database iss","author":"T Liu","year":"2007","unstructured":"Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35(Database issue):D198\u2013201. https:\/\/doi.org\/10.1093\/nar\/gkl999. From NLM Medline","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"3_CR65","doi-asserted-by":"publisher","first-page":"D1465","DOI":"10.1093\/nar\/gkad751","volume":"52","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F (2024) TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res 52(D1):D1465\u2013D1477. https:\/\/doi.org\/10.1093\/nar\/gkad751. From NLM Medline","journal-title":"Nucleic Acids Res"},{"issue":"7428","key":"3_CR66","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11691","volume":"492","author":"J Besnard","year":"2012","unstructured":"Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, Webster LA et al (2012) Automated design of ligands to polypharmacological profiles. Nature 492(7428):215\u2013220. https:\/\/doi.org\/10.1038\/nature11691. From NLM Medline","journal-title":"Nature"},{"issue":"D1","key":"3_CR67","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"S Kim","year":"2023","unstructured":"Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B et al (2023) PubChem 2023 update. Nucleic Acids Res 51(D1):D1373\u2013D1380. https:\/\/doi.org\/10.1093\/nar\/gkac956. From NLM Medline","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"3_CR68","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1021\/acs.jcim.1c00856","volume":"61","author":"KH Lee","year":"2021","unstructured":"Lee KH, Fant AD, Guo J, Guan A, Jung J, Kudaibergenova M, Miranda WE, Ku T, Cao J, Wacker S et al (2021) Toward reducing hERG affinities for DAT inhibitors with a combined machine learning and molecular modeling approach. J Chem Inf Model 61(9):4266\u20134279. https:\/\/doi.org\/10.1021\/acs.jcim.1c00856. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"5","key":"3_CR69","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1021\/jm00227a030","volume":"19","author":"J Tuomisto","year":"1976","unstructured":"Tuomisto J, Tuomisto L, Pazdernik TL (1976) Conformationally rigid amphetamine analogs as inhibitors of monoamine uptake by brain synaptosomes. J Med Chem 19(5):725\u2013727. https:\/\/doi.org\/10.1021\/jm00227a030. From NLM Medline","journal-title":"J Med Chem"},{"issue":"7056","key":"3_CR70","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature03978","volume":"437","author":"A Yamashita","year":"2005","unstructured":"Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E (2005) Crystal structure of a bacterial homologue of Na+\/Cl--dependent neurotransmitter transporters. Nature 437(7056):215\u2013223. https:\/\/doi.org\/10.1038\/nature03978. From NLM Medline","journal-title":"Nature"},{"issue":"2","key":"3_CR71","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1021\/cn300148r","volume":"4","author":"H Koldso","year":"2013","unstructured":"Koldso H, Christiansen AB, Sinning S, Schiott B (2013) Comparative modeling of the human monoamine transporters: similarities in substrate binding. ACS Chem Neurosci 4(2):295\u2013309. https:\/\/doi.org\/10.1021\/cn300148r. From NLM Medline","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"3_CR72","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1124\/mol.113.088922","volume":"85","author":"K Severinsen","year":"2014","unstructured":"Severinsen K, Koldso H, Thorup KA, Schjoth-Eskesen C, Moller PT, Wiborg O, Jensen HH, Sinning S, Schiott B (2014) Binding of mazindol and analogs to the human serotonin and dopamine transporters. Mol Pharmacol 85(2):208\u2013217. https:\/\/doi.org\/10.1124\/mol.113.088922. From NLM Medline","journal-title":"Mol Pharmacol"},{"issue":"1","key":"3_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016350","volume":"6","author":"J Shan","year":"2011","unstructured":"Shan J, Javitch JA, Shi L, Weinstein H (2011) The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter. PLoS One 6(1):e16350. https:\/\/doi.org\/10.1371\/journal.pone.0016350. From NLM Medline","journal-title":"PLoS One"},{"issue":"11","key":"3_CR74","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.str.2015.09.001","volume":"23","author":"MH Cheng","year":"2015","unstructured":"Cheng MH, Bahar I (2015) Molecular mechanism of Dopamine transport by human Dopamine transporter. Structure 23(11):2171\u20132181. https:\/\/doi.org\/10.1016\/j.str.2015.09.001","journal-title":"Structure"},{"issue":"10","key":"3_CR75","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00894-009-0478-1","volume":"15","author":"AW Ravna","year":"2009","unstructured":"Ravna AW, Sylte I, Dahl SG (2009) Structure and localisation of drug binding sites on neurotransmitter transporters. J Mol Model 15(10):1155\u20131164. https:\/\/doi.org\/10.1007\/s00894-009-0478-1. From NLM Medline","journal-title":"J Mol Model"},{"issue":"7474","key":"3_CR76","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nature12533","volume":"503","author":"A Penmatsa","year":"2013","unstructured":"Penmatsa A, Wang KH, Gouaux E (2013) X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503(7474):85\u201390. https:\/\/doi.org\/10.1038\/nature12533. From NLM Medline","journal-title":"Nature"},{"issue":"1","key":"3_CR77","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.111.191056","volume":"346","author":"KC Schmitt","year":"2013","unstructured":"Schmitt KC, Rothman RB, Reith ME (2013) Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. J Pharmacol Exp Ther 346(1):2\u201310. https:\/\/doi.org\/10.1124\/jpet.111.191056. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"3_CR78","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0014-2999(95)00698-2","volume":"296","author":"SJ Gatley","year":"1996","unstructured":"Gatley SJ, Volkow ND, Chen R, Fowler JS, Carroll FI, Kuhar MJ (1996) Displacement of RTI-55 from the dopamine transporter by cocaine. Eur J Pharmacol 296(2):145\u2013151. https:\/\/doi.org\/10.1016\/0014-2999(95)00698-2. From NLM Medline","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3_CR79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0165-0270(94)90022-1","volume":"51","author":"LL Coffey","year":"1994","unstructured":"Coffey LL, Reith ME (1994) [3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition. J Neurosci Methods 51(1):23\u201330. https:\/\/doi.org\/10.1016\/0165-0270(94)90022-1. From NLM Medline","journal-title":"J Neurosci Methods"},{"issue":"43","key":"3_CR80","doi-asserted-by":"publisher","first-page":"29712","DOI":"10.1074\/jbc.M114.571521","volume":"289","author":"RA Dahal","year":"2014","unstructured":"Dahal RA, Pramod AB, Sharma B, Krout D, Foster JD, Cha JH, Cao J, Newman AH, Lever JR, Vaughan RA et al (2014) Computational and biochemical docking of the irreversible cocaine analog RTI 82 directly demonstrates ligand positioning in the dopamine transporter central substrate-binding site. J Biol Chem 289(43):29712\u201329727. https:\/\/doi.org\/10.1074\/jbc.M114.571521. From NLM Medline","journal-title":"J Biol Chem"},{"issue":"4","key":"3_CR81","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1124\/mol.107.043679","volume":"73","author":"ML Parnas","year":"2008","unstructured":"Parnas ML, Gaffaney JD, Zou MF, Lever JR, Newman AH, Vaughan RA (2008) Labeling of dopamine transporter transmembrane domain 1 with the tropane ligand N-[4-(4-azido-3-[125I]iodophenyl)butyl]-2beta-carbomethoxy-3beta-(4-chlorophenyl)tropane implicates proximity of cocaine and substrate active sites. Mol Pharmacol 73(4):1141\u20131150. https:\/\/doi.org\/10.1124\/mol.107.043679. From NLM Medline","journal-title":"Mol Pharmacol"},{"issue":"3","key":"3_CR82","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/(SICI)1098-2396(199711)27:3<183::AID-SYN4>3.0.CO;2-9","volume":"27","author":"J Booij","year":"1997","unstructured":"Booij J, Andringa G, Rijks LJ, Vermeulen RJ, De Bruin K, Boer GJ, Janssen AG, Van Royen EA (1997) [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 27(3):183\u2013190. https:\/\/doi.org\/10.1002\/(SICI)1098-2396(199711)27:3<183::AID-SYN4>3.0.CO;2-9. From NLM Medline","journal-title":"Synapse"},{"issue":"2","key":"3_CR83","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/(SICI)1098-2396(199806)29:2<93::AID-SYN1>3.0.CO;2-5","volume":"29","author":"BK Madras","year":"1998","unstructured":"Madras BK, Meltzer PC, Liang AY, Elmaleh DR, Babich J, Fischman AJ (1998) Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse 29(2):93\u2013104. https:\/\/doi.org\/10.1002\/(SICI)1098-2396(199806)29:2<93::AID-SYN1>3.0.CO;2-5. From NLM Medline","journal-title":"Synapse"},{"issue":"1","key":"3_CR84","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0376-8716(01)00144-2","volume":"65","author":"HL Kimmel","year":"2001","unstructured":"Kimmel HL, Carroll FI, Kuhar MJ (2001) Locomotor stimulant effects of novel phenyltropanes in the mouse. Drug Alcohol Depend 65(1):25\u201336. https:\/\/doi.org\/10.1016\/s0376-8716(01)00144-2. From NLM Medline","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"3_CR85","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/sj.bjp.0707539","volume":"153","author":"T Lehr","year":"2008","unstructured":"Lehr T, Staab A, Tillmann C, Nielsen EO, Trommeshauser D, Schaefer HG, Kloft C (2008) Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol 153(1):164\u2013174. https:\/\/doi.org\/10.1038\/sj.bjp.0707539. From NLM Medline","journal-title":"Br J Pharmacol"},{"issue":"10","key":"3_CR86","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJM199903113401007","volume":"340","author":"J Elia","year":"1999","unstructured":"Elia J, Ambrosini PJ, Rapoport JL (1999) Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 340(10):780\u2013788. https:\/\/doi.org\/10.1056\/NEJM199903113401007. From NLM Medline","journal-title":"N Engl J Med"},{"issue":"1","key":"3_CR87","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0924-977x(03)00045-2","volume":"14","author":"S Kutcher","year":"2004","unstructured":"Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M et al (2004) International consensus statement on attention-deficit\/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14(1):11\u201328. https:\/\/doi.org\/10.1016\/s0924-977x(03)00045-2. From NLM Medline","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"3_CR88","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.schres.2004.12.019","volume":"77","author":"DM Barch","year":"2005","unstructured":"Barch DM, Carter CS (2005) Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 77(1):43\u201358. https:\/\/doi.org\/10.1016\/j.schres.2004.12.019. From NLM Medline","journal-title":"Schizophr Res"},{"issue":"2","key":"3_CR89","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/mp.2008.90","volume":"14","author":"SM Berman","year":"2009","unstructured":"Berman SM, Kuczenski R, McCracken JT, London ED (2009) Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry 14(2):123\u2013142. https:\/\/doi.org\/10.1038\/mp.2008.90. From NLM Medline","journal-title":"Mol Psychiatry"},{"key":"3_CR90","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fnins.2015.00069","volume":"9","author":"NA Northrop","year":"2015","unstructured":"Northrop NA, Yamamoto BK (2015) Methamphetamine effects on blood-brain barrier structure and function. Front Neurosci 9:69. https:\/\/doi.org\/10.3389\/fnins.2015.00069. From NLM PubMed-not-MEDLINE","journal-title":"Front Neurosci"},{"issue":"20","key":"3_CR91","doi-asserted-by":"publisher","first-page":"8417","DOI":"10.1523\/JNEUROSCI.18-20-08417.1998","volume":"18","author":"UD McCann","year":"1998","unstructured":"McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18(20):8417\u20138422. https:\/\/doi.org\/10.1523\/JNEUROSCI.18-20-08417.1998. From NLM Medline","journal-title":"J Neurosci"},{"issue":"9","key":"3_CR92","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamapsychiatry.2020.0246","volume":"77","author":"MP Paulus","year":"2020","unstructured":"Paulus MP, Stewart JL (2020) Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA Psychiatry 77(9):959\u2013966. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.0246. From NLM Medline","journal-title":"JAMA Psychiatry"},{"key":"3_CR93","volume-title":"StatPearls [Internet]","author":"D Martin","year":"2023","unstructured":"Martin D, Le JK (2023) Amphetamine [Updated 2023 Jul 31]. In: StatPearls [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556103\/. Accessed"},{"key":"3_CR94","first-page":"141","volume":"33(2)","author":"SL Erdo","year":"1981","unstructured":"Erdo SL, Kiss B, Rosdy B (1981) Inhibition of dopamine uptake by a new psychostimulant mesocarb (Sydnocarb). Pol J Pharmacol Pharm 33(2):141\u2013147. From NLM Medline","journal-title":"Pol J Pharmacol Pharm"},{"key":"3_CR95","doi-asserted-by":"publisher","unstructured":"Aggarwal S, Cheng MH, Salvino JM, Bahar I, Mortensen OV (2021) Functional characterization of the Dopaminergic psychostimulant Sydnocarb as an allosteric modulator of the human dopamine transporter. Biomedicines 9(6). https:\/\/doi.org\/10.3390\/biomedicines9060634. From NLM PubMed-not-MEDLINE","DOI":"10.3390\/biomedicines9060634"},{"issue":"7","key":"3_CR96","first-page":"917","volume":"165","author":"H Kalant","year":"2001","unstructured":"Kalant H (2001) The pharmacology and toxicology of \u201cecstasy\u201d (MDMA) and related drugs. CMAJ 165(7):917\u2013928. From NLM Medline","journal-title":"CMAJ"},{"issue":"1\u20132","key":"3_CR97","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1515\/BC.2011.016","volume":"392","author":"T Steinkellner","year":"2011","unstructured":"Steinkellner T, Freissmuth M, Sitte HH, Montgomery T (2011) The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, \u2019Ecstasy\u2019), methamphetamine and D-amphetamine. Biol Chem 392(1\u20132):103\u2013115. https:\/\/doi.org\/10.1515\/BC.2011.016. From NLM Medline","journal-title":"Biol Chem"},{"issue":"1","key":"3_CR98","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/157015911795017254","volume":"9","author":"Y Hagino","year":"2011","unstructured":"Hagino Y, Takamatsu Y, Yamamoto H, Iwamura T, Murphy DL, Uhl GR, Sora I, Ikeda K (2011) Effects of MDMA on extracellular Dopamine and Serotonin levels in mice lacking Dopamine and\/or Serotonin transporters. Curr Neuropharmacol 9(1):91\u201395. https:\/\/doi.org\/10.2174\/157015911795017254. From NLM PubMed-not-MEDLINE","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"3_CR99","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/jpet.111.188946","volume":"341","author":"RB Rothman","year":"2012","unstructured":"Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE (2012) Studies of the biogenic amine transporters. 14. Identification of low-efficacy \u201cpartial\u201d substrates for the biogenic amine transporters. J Pharmacol Exp Ther 341(1):251\u2013262. https:\/\/doi.org\/10.1124\/jpet.111.188946. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"17","key":"3_CR100","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2174\/156802606778249766","volume":"6","author":"RB Rothman","year":"2006","unstructured":"Rothman RB, Baumann MH (2006) Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem 6(17):1845\u20131859. https:\/\/doi.org\/10.2174\/156802606778249766. From NLM Medline","journal-title":"Curr Top Med Chem"},{"issue":"3","key":"3_CR101","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00213-018-5052-z","volume":"236","author":"R Lopez-Arnau","year":"2019","unstructured":"Lopez-Arnau R, Duart-Castells L, Aster B, Camarasa J, Escubedo E, Pubill D (2019) Effects of MDPV on dopamine transporter regulation in male rats. Comparison with cocaine. Psychopharmacology 236(3):925\u2013938. https:\/\/doi.org\/10.1007\/s00213-018-5052-z. From NLM Medline","journal-title":"Psychopharmacology"},{"issue":"4","key":"3_CR102","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/npp.2012.204","volume":"38","author":"MH Baumann","year":"2013","unstructured":"Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH et al (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive \u2019bath salts\u2019 products. Neuropsychopharmacology 38(4):552\u2013562. https:\/\/doi.org\/10.1038\/npp.2012.204. From NLM Medline","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"3_CR103","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00213-006-0322-6","volume":"189","author":"MH Baumann","year":"2007","unstructured":"Baumann MH, Wang X, Rothman RB (2007) 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology 189(4):407\u2013424. https:\/\/doi.org\/10.1007\/s00213-006-0322-6. From NLM Medline","journal-title":"Psychopharmacology"},{"issue":"11","key":"3_CR104","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1001\/jama.2009.351","volume":"301","author":"ND Volkow","year":"2009","unstructured":"Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, Wang GJ, Jayne M, Hooker JM, Wong C et al (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301(11):1148\u20131154. https:\/\/doi.org\/10.1001\/jama.2009.351. From NLM Medline","journal-title":"JAMA"},{"issue":"6","key":"3_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179675","volume":"12","author":"B Shanmugasundaram","year":"2017","unstructured":"Shanmugasundaram B, Aher YD, Aradska J, Ilic M, Daba Feyissa D, Kalaba P, Aher NY, Dragacevic V, Saber Marouf B, Langer T et al (2017) R-Modafinil exerts weak effects on spatial memory acquisition and dentate gyrus synaptic plasticity. PLoS One 12(6):e0179675. https:\/\/doi.org\/10.1371\/journal.pone.0179675. From NLM Medline","journal-title":"PLoS One"},{"key":"3_CR106","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fphar.2019.00682","volume":"10","author":"RA Rotolo","year":"2019","unstructured":"Rotolo RA, Dragacevic V, Kalaba P, Urban E, Zehl M, Roller A, Wackerlig J, Langer T, Pistis M, De Luca MA et al (2019) The novel atypical Dopamine uptake inhibitor (S)-CE-123 partially reverses the effort-related effects of the Dopamine depleting agent Tetrabenazine and increases progressive ratio responding. Front Pharmacol 10:682. https:\/\/doi.org\/10.3389\/fphar.2019.00682. From NLM PubMed-not-MEDLINE","journal-title":"Front Pharmacol"},{"issue":"1\u20133","key":"3_CR107","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejphar.2012.03.003","volume":"683","author":"EB Oleson","year":"2012","unstructured":"Oleson EB, Ferris MJ, Espana RA, Harp J, Jones SR (2012) Effects of the histamine H(1) receptor antagonist and benztropine analog diphenylpyraline on dopamine uptake, locomotion and reward. Eur J Pharmacol 683(1\u20133):161\u2013165. https:\/\/doi.org\/10.1016\/j.ejphar.2012.03.003. From NLM Medline","journal-title":"Eur J Pharmacol"},{"issue":"2\u20133","key":"3_CR108","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0014-2999(97)01393-9","volume":"340","author":"M Tatsumi","year":"1997","unstructured":"Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340(2\u20133):249\u2013258. https:\/\/doi.org\/10.1016\/s0014-2999(97)01393-9. From NLM Medline","journal-title":"Eur J Pharmacol"},{"key":"3_CR109","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2174\/0929867305666220314215936","volume":"5(4)","author":"AH Newman","year":"1998","unstructured":"Newman AH, Agoston GE (1998) Novel benztropine [3a-(diphenylmethoxy)tropane] analogs as probes for the dopamine transporter. Curr Med Chem 5(4):305\u2013319. From NLM Medline","journal-title":"Curr Med Chem"},{"issue":"3","key":"3_CR110","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/jpet.110.171629","volume":"335","author":"TA Kopajtic","year":"2010","unstructured":"Kopajtic TA, Liu Y, Surratt CK, Donovan DM, Newman AH, Katz JL (2010) Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability. J Pharmacol Exp Ther 335(3):703\u2013714. https:\/\/doi.org\/10.1124\/jpet.110.171629. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"3_CR111","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1124\/jpet.118.250902","volume":"367","author":"MJ Moerke","year":"2018","unstructured":"Moerke MJ, Ananthan S, Banks ML, Eltit JM, Freitas KC, Johnson AR, Saini SK, Steele TWE, Negus SS (2018) Interactions between Cocaine and the putative allosteric Dopamine transporter ligand SRI-31142. J Pharmacol Exp Ther 367(2):222\u2013233. https:\/\/doi.org\/10.1124\/jpet.118.250902. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"3_CR112","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/syn.10046","volume":"43","author":"RB Rothman","year":"2002","unstructured":"Rothman RB, Dersch CM, Carroll FI, Ananthan S (2002) Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding. Synapse 43(4):268\u2013274. https:\/\/doi.org\/10.1002\/syn.10046. From NLM Medline","journal-title":"Synapse"},{"issue":"1","key":"3_CR113","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1124\/jpet.108.139675","volume":"326","author":"JJ Pariser","year":"2008","unstructured":"Pariser JJ, Partilla JS, Dersch CM, Ananthan S, Rothman RB (2008) Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release. J Pharmacol Exp Ther 326(1):286\u2013295. https:\/\/doi.org\/10.1124\/jpet.108.139675. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"3_CR114","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0022-3565(24)37161-7","volume":"283","author":"MJ Owens","year":"1997","unstructured":"Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283(3):1305\u20131322. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"3 Suppl B","key":"3_CR115","doi-asserted-by":"publisher","first-page":"S5\u201320","DOI":"10.1177\/0269881198012003021","volume":"12","author":"PJ Goodnick","year":"1998","unstructured":"Goodnick PJ, Goldstein BJ (1998) Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology. J Psychopharmacol 12(3 Suppl B):S5\u201320. https:\/\/doi.org\/10.1177\/0269881198012003021. From NLM Medline","journal-title":"J Psychopharmacol"},{"issue":"12","key":"3_CR116","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1038\/npp.2015.124","volume":"40","author":"KS Koblan","year":"2015","unstructured":"Koblan KS, Hopkins SC, Sarma K, Jin F, Goldman R, Kollins SH, Loebel A (2015) Dasotraline for the treatment of attention-deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology 40(12):2745\u20132752. https:\/\/doi.org\/10.1038\/npp.2015.124. From NLM Medline","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"3_CR117","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","volume":"20","author":"CP Lawler","year":"1999","unstructured":"Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20(6):612\u2013627. https:\/\/doi.org\/10.1016\/S0893-133X(98)00099-2. From NLM Medline","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"3_CR118","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1527-3458.2004.tb00030.x","volume":"10","author":"MA Davies","year":"2004","unstructured":"Davies MA, Sheffler DJ, Roth BL (2004) Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 10(4):317\u2013336. https:\/\/doi.org\/10.1111\/j.1527-3458.2004.tb00030.x. From NLM Medline","journal-title":"CNS Drug Rev"},{"issue":"11","key":"3_CR119","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/070674370304801116","volume":"48","author":"HS Duggal","year":"2003","unstructured":"Duggal HS (2003) Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatr 48(11):771\u2013772. https:\/\/doi.org\/10.1177\/070674370304801116. From NLM Medline","journal-title":"Can J Psychiatr"},{"issue":"5","key":"3_CR120","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/s0960-894x(98)00062-6","volume":"8","author":"PR Carlier","year":"1998","unstructured":"Carlier PR, Lo MM, Lo PC, Richelson E, Tatsumi M, Reynolds IJ, Sharma TA (1998) Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg Med Chem Lett 8(5):487\u2013492. https:\/\/doi.org\/10.1016\/s0960-894x(98)00062-6. From NLM Medline","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"3_CR121","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1527-3458.2002.tb00234.x","volume":"8","author":"KD Karpa","year":"2002","unstructured":"Karpa KD, Cavanaugh JE, Lakoski JM (2002) Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev 8(4):361\u2013376. https:\/\/doi.org\/10.1111\/j.1527-3458.2002.tb00234.x. From NLM Medline","journal-title":"CNS Drug Rev"},{"issue":"19","key":"3_CR122","doi-asserted-by":"publisher","first-page":"6890","DOI":"10.1016\/j.bmc.2009.08.025","volume":"17","author":"JR Cashman","year":"2009","unstructured":"Cashman JR, Ghirmai S (2009) Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem 17(19):6890\u20136897. https:\/\/doi.org\/10.1016\/j.bmc.2009.08.025. From NLM Medline","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"3_CR123","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1124\/jpet.104.082503","volume":"313","author":"RB Rothman","year":"2005","unstructured":"Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, Baumann MH (2005) Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther 313(3):1361\u20131369. https:\/\/doi.org\/10.1124\/jpet.104.082503. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"3_CR124","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1124\/mol.118.114793","volume":"95","author":"PS Hasenhuetl","year":"2019","unstructured":"Hasenhuetl PS, Bhat S, Freissmuth M, Sandtner W (2019) Functional selectivity and partial efficacy at the Monoamine transporters: a unified model of allosteric modulation and amphetamine-induced substrate release. Mol Pharmacol 95(3):303\u2013312. https:\/\/doi.org\/10.1124\/mol.118.114793. From NLM Medline","journal-title":"Mol Pharmacol"},{"issue":"1","key":"3_CR125","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0014-2999(02)01830-7","volume":"447","author":"RB Rothman","year":"2002","unstructured":"Rothman RB, Katsnelson M, Vu N, Partilla JS, Dersch CM, Blough BE, Baumann MH (2002) Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol 447(1):51\u201357. https:\/\/doi.org\/10.1016\/s0014-2999(02)01830-7. From NLM Medline","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3_CR126","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coph.2004.10.001","volume":"5","author":"KC Fone","year":"2005","unstructured":"Fone KC, Nutt DJ (2005) Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol 5(1):87\u201393. https:\/\/doi.org\/10.1016\/j.coph.2004.10.001. From NLM Medline","journal-title":"Curr Opin Pharmacol"},{"key":"3_CR127","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/B978-0-12-820472-6.00164-X","volume-title":"Comprehensive pharmacology","author":"P Marco","year":"2022","unstructured":"Marco P, Maddalena M, Silvana B, Erika G, Maria N (2022) Attention deficit hyperactivity disorder. In: Comprehensive pharmacology, pp 256\u2013285"},{"issue":"1","key":"3_CR128","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00210-004-0949-y","volume":"370","author":"DM Raffel","year":"2004","unstructured":"Raffel DM, Chen W (2004) Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedeberg\u2019s Arch Pharmacol 370(1):9\u201316. https:\/\/doi.org\/10.1007\/s00210-004-0949-y. From NLM Medline","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"2","key":"3_CR129","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1124\/jpet.111.185025","volume":"339","author":"T Hiranita","year":"2011","unstructured":"Hiranita T, Soto PL, Kohut SJ, Kopajtic T, Cao J, Newman AH, Tanda G, Katz JL (2011) Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and sigma receptors. J Pharmacol Exp Ther 339(2):662\u2013677. https:\/\/doi.org\/10.1124\/jpet.111.185025. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"key":"3_CR130","doi-asserted-by":"publisher","first-page":"81043","DOI":"10.52965\/001c.81043","volume":"11","author":"A Clark","year":"2023","unstructured":"Clark A, Tate B, Urban B, Schroeder R, Gennuso S, Ahmadzadeh S, McGregor D, Girma B, Shekoohi S, Kaye AD (2023) Bupropion mediated effects on depression, attention deficit hyperactivity disorder, and smoking cessation. Health Psychol Res 11:81043. https:\/\/doi.org\/10.52965\/001c.81043. From NLM PubMed-not-MEDLINE","journal-title":"Health Psychol Res"},{"issue":"1","key":"3_CR131","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1124\/jpet.118.248179","volume":"367","author":"SR Mikelman","year":"2018","unstructured":"Mikelman SR, Guptaroy B, Schmitt KC, Jones KT, Zhen J, Reith MEA, Gnegy ME (2018) Tamoxifen directly interacts with the Dopamine transporter. J Pharmacol Exp Ther 367(1):119\u2013128. https:\/\/doi.org\/10.1124\/jpet.118.248179. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"22","key":"3_CR132","doi-asserted-by":"publisher","first-page":"18524","DOI":"10.1074\/jbc.M112.343681","volume":"287","author":"S Bulling","year":"2012","unstructured":"Bulling S, Schicker K, Zhang YW, Steinkellner T, Stockner T, Gruber CW, Boehm S, Freissmuth M, Rudnick G, Sitte HH et al (2012) The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. J Biol Chem 287(22):18524\u201318534. https:\/\/doi.org\/10.1074\/jbc.M112.343681. From NLM Medline","journal-title":"J Biol Chem"},{"issue":"23","key":"3_CR133","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Y Cheng","year":"1973","unstructured":"Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22(23):3099\u20133108. https:\/\/doi.org\/10.1016\/0006-2952(73)90196-2. From NLM Medline","journal-title":"Biochem Pharmacol"},{"issue":"7873","key":"3_CR134","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Zidek A, Potapenko A et al (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596(7873):583\u2013589. https:\/\/doi.org\/10.1038\/s41586-021-03819-2. From NLM Medline","journal-title":"Nature"},{"key":"3_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cbpa.2021.04.005","volume":"65","author":"M AlQuraishi","year":"2021","unstructured":"AlQuraishi M (2021) Machine learning in protein structure prediction. Curr Opin Chem Biol 65:1\u20138. https:\/\/doi.org\/10.1016\/j.cbpa.2021.04.005. From NLM Medline","journal-title":"Curr Opin Chem Biol"},{"issue":"3","key":"3_CR136","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1021\/acs.jcim.8b00785","volume":"59","author":"J Wenzel","year":"2019","unstructured":"Wenzel J, Matter H, Schmidt F (2019) Predictive multitask deep neural network models for ADME-Tox properties: learning from large data sets. J Chem Inf Model 59(3):1253\u20131268. https:\/\/doi.org\/10.1021\/acs.jcim.8b00785. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"2","key":"3_CR137","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1021\/acs.jcim.7b00558","volume":"58","author":"K Wu","year":"2018","unstructured":"Wu K, Wei GW (2018) Quantitative toxicity prediction using topology based multitask deep neural networks. J Chem Inf Model 58(2):520\u2013531. https:\/\/doi.org\/10.1021\/acs.jcim.7b00558. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"16","key":"3_CR138","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1021\/acs.jcim.3c00651","volume":"63","author":"L Salas-Estrada","year":"2023","unstructured":"Salas-Estrada L, Provasi D, Qiu X, Kaniskan HU, Huang XP, DiBerto JF, Lamim Ribeiro JM, Jin J, Roth BL, Filizola M (2023) De Novo design of kappa-opioid receptor antagonists using a generative deep-learning framework. J Chem Inf Model 63(16):5056\u20135065. https:\/\/doi.org\/10.1021\/acs.jcim.3c00651. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"11","key":"3_CR139","doi-asserted-by":"publisher","first-page":"973-+","DOI":"10.1038\/s42256-021-00407-x","volume":"3","author":"MA Skinnider","year":"2021","unstructured":"Skinnider MA, Wang F, Pasin D, Greiner R, Foster LJ, Dalsgaard PW, Wishart DS (2021) A deep generative model enables automated structure elucidation of novel psychoactive substances. Nat Mach Intell 3(11):973-+. https:\/\/doi.org\/10.1038\/s42256-021-00407-x","journal-title":"Nat Mach Intell"},{"issue":"20","key":"3_CR140","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1021\/acs.jcim.2c00838","volume":"62","author":"SR Atance","year":"2022","unstructured":"Atance SR, Diez JV, Engkvist O, Olsson S, Mercado R (2022) De Novo drug design using reinforcement learning with graph-based deep generative models. J Chem Inf Model 62(20):4863\u20134872. https:\/\/doi.org\/10.1021\/acs.jcim.2c00838. From NLM Medline","journal-title":"J Chem Inf Model"},{"key":"3_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.858126","volume":"16","author":"R Kumar","year":"2022","unstructured":"Kumar R, Sharma A, Alexiou A, Bilgrami AL, Kamal MA, Ashraf GM (2022) DeePred-BBB: a blood brain barrier permeability prediction model with improved accuracy. Front Neurosci 16:858126. https:\/\/doi.org\/10.3389\/fnins.2022.858126. From NLM PubMed-not-MEDLINE","journal-title":"Front Neurosci"},{"key":"3_CR142","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-1-0716-1787-8_10","volume":"2390","author":"Y Xu","year":"2022","unstructured":"Xu Y (2022) Deep neural networks for QSAR. Methods Mol Biol 2390:233\u2013260. https:\/\/doi.org\/10.1007\/978-1-0716-1787-8_10. From NLM Medline","journal-title":"Methods Mol Biol"},{"issue":"12","key":"3_CR143","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1021\/acs.jcim.0c00884","volume":"60","author":"VB Siramshetty","year":"2020","unstructured":"Siramshetty VB, Nguyen DT, Martinez NJ, Southall NT, Simeonov A, Zakharov AV (2020) Critical assessment of artificial intelligence methods for prediction of hERG channel inhibition in the \u201cBig Data\u201d era. J Chem Inf Model 60(12):6007\u20136019. https:\/\/doi.org\/10.1021\/acs.jcim.0c00884. From NLM Medline","journal-title":"J Chem Inf Model"},{"key":"3_CR144","doi-asserted-by":"publisher","unstructured":"Wu Z, Zhu M, Kang Y, Leung EL, Lei T, Shen C, Jiang D, Wang Z, Cao D, Hou T (2021) Do we need different machine learning algorithms for QSAR modeling? A comprehensive assessment of 16 machine learning algorithms on 14 QSAR data sets. Brief Bioinform 22(4). https:\/\/doi.org\/10.1093\/bib\/bbaa321. From NLM Medline","DOI":"10.1093\/bib\/bbaa321"},{"issue":"4","key":"3_CR145","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1021\/acs.jctc.2c00002","volume":"18","author":"H Feng","year":"2022","unstructured":"Feng H, Gao K, Chen D, Shen L, Robison AJ, Ellsworth E, Wei GW (2022) Machine learning analysis of cocaine addiction informed by DAT, SERT, and NET-based interactome networks. J Chem Theory Comput 18(4):2703\u20132719. https:\/\/doi.org\/10.1021\/acs.jctc.2c00002. From NLM Medline","journal-title":"J Chem Theory Comput"},{"issue":"5","key":"3_CR146","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1021\/acs.jcim.3c00046","volume":"63","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Dou B, Cao Y, Jiang J, Zhu Y, Chen D, Feng H, Liu J, Zhang B, Zhou T et al (2023) TIDAL: topology-inferred drug addiction learning. J Chem Inf Model 63(5):1472\u20131489. https:\/\/doi.org\/10.1021\/acs.jcim.3c00046. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"4","key":"3_CR147","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1021\/acscentsci.6b00367","volume":"3","author":"H Altae-Tran","year":"2017","unstructured":"Altae-Tran H, Ramsundar B, Pappu AS, Pande V (2017) Low data drug discovery with one-shot learning. ACS Cent Sci 3(4):283\u2013293. https:\/\/doi.org\/10.1021\/acscentsci.6b00367. From NLM PubMed-not-MEDLINE","journal-title":"ACS Cent Sci"},{"key":"3_CR148","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.inffus.2021.11.011","volume":"81","author":"R Shwartz-Ziv","year":"2022","unstructured":"Shwartz-Ziv R, Armon A (2022) Tabular data: deep learning is not all you need. Inf Fusion 81:84\u201390. https:\/\/doi.org\/10.1016\/j.inffus.2021.11.011","journal-title":"Inf Fusion"},{"issue":"4","key":"3_CR149","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1021\/acs.jcim.8b00820","volume":"59","author":"C Garcia-Hernandez","year":"2019","unstructured":"Garcia-Hernandez C, Fernandez A, Serratosa F (2019) Ligand-based virtual screening using graph edit distance as molecular similarity measure. J Chem Inf Model 59(4):1410\u20131421. https:\/\/doi.org\/10.1021\/acs.jcim.8b00820. From NLM Medline","journal-title":"J Chem Inf Model"},{"key":"3_CR150","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ymeth.2014.08.005","volume":"71","author":"A Cereto-Massague","year":"2015","unstructured":"Cereto-Massague A, Ojeda MJ, Valls C, Mulero M, Garcia-Vallve S, Pujadas G (2015) Molecular fingerprint similarity search in virtual screening. Methods 71:58\u201363. https:\/\/doi.org\/10.1016\/j.ymeth.2014.08.005. From NLM Medline","journal-title":"Methods"},{"issue":"3","key":"3_CR151","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1021\/ci400742s","volume":"54","author":"M Gabrielsen","year":"2014","unstructured":"Gabrielsen M, Kurczab R, Siwek A, Wolak M, Ravna AW, Kristiansen K, Kufareva I, Abagyan R, Nowak G, Chilmonczyk Z et al (2014) Identification of novel serotonin transporter compounds by virtual screening. J Chem Inf Model 54(3):933\u2013943. https:\/\/doi.org\/10.1021\/ci400742s. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"Suppl 1","key":"3_CR152","doi-asserted-by":"publisher","first-page":"S2233","DOI":"10.3233\/BME-151529","volume":"26","author":"P Wang","year":"2015","unstructured":"Wang P, Yang F, Yang H, Xu X, Liu D, Xue W, Zhu F (2015) Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods. Biomed Mater Eng 26(Suppl 1):S2233\u2013S2239. https:\/\/doi.org\/10.3233\/BME-151529. From NLM Medline","journal-title":"Biomed Mater Eng"},{"key":"3_CR153","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jmgm.2017.02.001","volume":"74","author":"I Erol","year":"2017","unstructured":"Erol I, Aksoydan B, Kantarcioglu I, Salmas RE, Durdagi S (2017) Identification of novel serotonin reuptake inhibitors targeting central and allosteric binding sites: a virtual screening and molecular dynamics simulations study. J Mol Graph Model 74:193\u2013202. https:\/\/doi.org\/10.1016\/j.jmgm.2017.02.001. From NLM Medline","journal-title":"J Mol Graph Model"},{"issue":"8","key":"3_CR154","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.1074\/jbc.274.8.4876","volume":"274","author":"JL Berfield","year":"1999","unstructured":"Berfield JL, Wang LC, Reith ME (1999) Which form of dopamine is the substrate for the human dopamine transporter: the cationic or the uncharged species? J Biol Chem 274(8):4876\u20134882. https:\/\/doi.org\/10.1074\/jbc.274.8.4876. From NLM Medline","journal-title":"J Biol Chem"},{"issue":"1\u20133","key":"3_CR155","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/s0014-2999(00)00563-x","volume":"405","author":"N Chen","year":"2000","unstructured":"Chen N, Reith ME (2000) Structure and function of the dopamine transporter. Eur J Pharmacol 405(1\u20133):329\u2013339. https:\/\/doi.org\/10.1016\/s0014-2999(00)00563-x. From NLM Medline","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"3_CR156","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","volume":"21","author":"JC Shelley","year":"2007","unstructured":"Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M (2007) Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 21(12):681\u2013691. https:\/\/doi.org\/10.1007\/s10822-007-9133-z. From NLM Medline","journal-title":"J Comput Aided Mol Des"},{"issue":"7","key":"3_CR157","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1021\/acs.jcim.1c00075","volume":"61","author":"X Pan","year":"2021","unstructured":"Pan X, Wang H, Li C, Zhang JZH, Ji C (2021) MolGpka: a web server for small molecule pK(a) prediction using a graph-convolutional neural network. J Chem Inf Model 61(7):3159\u20133165. https:\/\/doi.org\/10.1021\/acs.jcim.1c00075. From NLM Medline","journal-title":"J Chem Inf Model"},{"issue":"2","key":"3_CR158","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1021\/jm9505324","volume":"39","author":"JL Neumeyer","year":"1996","unstructured":"Neumeyer JL, Tamagnan G, Wang S, Gao Y, Milius RA, Kula NS, Baldessarini RJ (1996) N-substituted analogs of 2 beta-carbomethoxy-3 beta- (4\u2032-iodophenyl)tropane (beta-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 39(2):543\u2013548. https:\/\/doi.org\/10.1021\/jm9505324. From NLM Medline","journal-title":"J Med Chem"},{"issue":"9","key":"3_CR159","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.bmcl.2004.02.043","volume":"14","author":"F Bois","year":"2004","unstructured":"Bois F, Baldwin RM, Kula NS, Baldessarini RJ, Innis RB, Tamagnan G (2004) Synthesis and monoamine transporter affinity of 3\u2032-analogs of 2-beta-carbomethoxy-3-beta-(4\u2032-iodophenyl)tropane (beta-CIT). Bioorg Med Chem Lett 14(9):2117\u20132120. https:\/\/doi.org\/10.1016\/j.bmcl.2004.02.043. From NLM Medline","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"3_CR160","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1124\/jpet.114.222299","volume":"353","author":"RB Rothman","year":"2015","unstructured":"Rothman RB, Ananthan S, Partilla JS, Saini SK, Moukha-Chafiq O, Pathak V, Baumann MH (2015) Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency. J Pharmacol Exp Ther 353(3):529\u2013538. https:\/\/doi.org\/10.1124\/jpet.114.222299. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"3_CR161","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1021\/acs.jmedchem.6b01827","volume":"61","author":"MAM Subbaiah","year":"2018","unstructured":"Subbaiah MAM (2018) Triple reuptake inhibitors as potential therapeutics for depression and other disorders: design paradigm and developmental challenges. J Med Chem 61(6):2133\u20132165. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01827. From NLM Medline","journal-title":"J Med Chem"},{"issue":"7","key":"3_CR162","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1021\/acs.jmedchem.7b00085","volume":"60","author":"RA Glennon","year":"2017","unstructured":"Glennon RA (2017) The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: the \u201cPhenylalkylaminome\u201d with a focus on selected drugs of abuse. J Med Chem 60(7):2605\u20132628. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00085. From NLM Medline","journal-title":"J Med Chem"},{"issue":"9","key":"3_CR163","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1021\/jm701270n","volume":"51","author":"LW Hsin","year":"2008","unstructured":"Hsin LW, Chang LT, Rothman RB, Dersch CM, Jacobson AE, Rice KC (2008) Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters. J Med Chem 51(9):2795\u20132806. https:\/\/doi.org\/10.1021\/jm701270n. From NLM Medline","journal-title":"J Med Chem"},{"issue":"11","key":"3_CR164","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1016\/j.bmcl.2013.03.066","volume":"23","author":"W Arunotayanun","year":"2013","unstructured":"Arunotayanun W, Dalley JW, Huang XP, Setola V, Treble R, Iversen L, Roth BL, Gibbons S (2013) An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging \u2019Novel Psychoactive Drugs\u2019. Bioorg Med Chem Lett 23(11):3411\u20133415. https:\/\/doi.org\/10.1016\/j.bmcl.2013.03.066. From NLM Medline","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"3_CR165","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1021\/ml300262e","volume":"4","author":"DG Brown","year":"2013","unstructured":"Brown DG, Bernstein PR, Wu Y, Urbanek RA, Becker CW, Throner SR, Dembofsky BT, Steelman GB, Lazor LA, Scott CW et al (2013) Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity. ACS Med Chem Lett 4(1):46\u201351. https:\/\/doi.org\/10.1021\/ml300262e. From NLM PubMed-not-MEDLINE","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"3_CR166","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1124\/jpet.111.178947","volume":"337","author":"JA Gruner","year":"2011","unstructured":"Gruner JA, Mathiasen JR, Flood DG, Gasior M (2011) Characterization of pharmacological and wake-promoting properties of the dopaminergic stimulant sydnocarb in rats. J Pharmacol Exp Ther 337(2):380\u2013390. https:\/\/doi.org\/10.1124\/jpet.111.178947. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"23","key":"3_CR167","doi-asserted-by":"publisher","first-page":"10676","DOI":"10.1021\/acs.jmedchem.6b01373","volume":"59","author":"J Cao","year":"2016","unstructured":"Cao J, Slack RD, Bakare OM, Burzynski C, Rais R, Slusher BS, Kopajtic T, Bonifazi A, Ellenberger MP, Yano H et al (2016) Novel and high affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) analogues as atypical Dopamine transporter inhibitors. J Med Chem 59(23):10676\u201310691. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01373. From NLM Medline","journal-title":"J Med Chem"},{"issue":"8","key":"3_CR168","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1039\/c6md00245e","volume":"7","author":"AM Decker","year":"2016","unstructured":"Decker AM, Partilla JS, Baumann MH, Rothman RB, Blough BE (2016) The biogenic amine transporter activity of vinylogous amphetamine analogs. Medchemcomm 7(8):1657\u20131663. https:\/\/doi.org\/10.1039\/c6md00245e","journal-title":"Medchemcomm"},{"issue":"4","key":"3_CR169","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.bmc.2012.01.014","volume":"20","author":"S Mavel","year":"2012","unstructured":"Mavel S, Mincheva Z, Meheux N, Carcenac Y, Guilloteau D, Abarbri M, Emond P (2012) QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT). Bioorg Med Chem 20(4):1388\u20131395. https:\/\/doi.org\/10.1016\/j.bmc.2012.01.014. From NLM Medline","journal-title":"Bioorg Med Chem"},{"issue":"25","key":"3_CR170","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1021\/jm0101904","volume":"44","author":"MF Zou","year":"2001","unstructured":"Zou MF, Kopajtic T, Katz JL, Wirtz S, Justice JB Jr, Newman AH (2001) Novel tropane-based irreversible ligands for the dopamine transporter. J Med Chem 44(25):4453\u20134461. https:\/\/doi.org\/10.1021\/jm0101904. From NLM Medline","journal-title":"J Med Chem"},{"issue":"25","key":"3_CR171","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1021\/jm0309349","volume":"46","author":"A Orjales","year":"2003","unstructured":"Orjales A, Mosquera R, Toledo A, Pumar MC, Garcia N, Cortizo L, Labeaga L, Innerarity A (2003) Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters. J Med Chem 46(25):5512\u20135532. https:\/\/doi.org\/10.1021\/jm0309349. From NLM Medline","journal-title":"J Med Chem"},{"issue":"7","key":"3_CR172","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1021\/acs.jmedchem.7b00141","volume":"60","author":"DK Tosh","year":"2017","unstructured":"Tosh DK, Janowsky A, Eshleman AJ, Warnick E, Gao ZG, Chen Z, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA (2017) Scaffold repurposing of nucleosides (Adenosine Receptor agonists): enhanced activity at the human Dopamine and Norepinephrine sodium symporters. J Med Chem 60(7):3109\u20133123. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00141. From NLM Medline","journal-title":"J Med Chem"},{"issue":"1","key":"3_CR173","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/FBP.0b013e3280143226","volume":"18","author":"RL Williard","year":"2007","unstructured":"Williard RL, Middaugh LD, Zhu HJ, Patrick KS (2007) Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol 18(1):39\u201351. https:\/\/doi.org\/10.1097\/FBP.0b013e3280143226. From NLM Medline","journal-title":"Behav Pharmacol"},{"issue":"9","key":"3_CR174","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0024-3205(90)90132-b","volume":"46","author":"MC Ritz","year":"1990","unstructured":"Ritz MC, Cone EJ, Kuhar MJ (1990) Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sci 46(9):635\u2013645. https:\/\/doi.org\/10.1016\/0024-3205(90)90132-b. From NLM Medline","journal-title":"Life Sci"},{"issue":"2","key":"3_CR175","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1021\/jm0608614","volume":"50","author":"M Froimowitz","year":"2007","unstructured":"Froimowitz M, Gu Y, Dakin LA, Nagafuji PM, Kelley CJ, Parrish D, Deschamps JR, Janowsky A (2007) Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem 50(2):219\u2013232. https:\/\/doi.org\/10.1021\/jm0608614. From NLM Medline","journal-title":"J Med Chem"},{"issue":"21","key":"3_CR176","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1021\/jm9902943","volume":"42","author":"SM Husbands","year":"1999","unstructured":"Husbands SM, Izenwasser S, Kopajtic T, Bowen WD, Vilner BJ, Katz JL, Newman AH (1999) Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues. J Med Chem 42(21):4446\u20134455. https:\/\/doi.org\/10.1021\/jm9902943. From NLM Medline","journal-title":"J Med Chem"},{"issue":"13","key":"3_CR177","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1016\/j.bmcl.2004.04.066","volume":"14","author":"F Kuo","year":"2004","unstructured":"Kuo F, Gillespie TA, Kulanthaivel P, Lantz RJ, Ma TW, Nelson DL, Threlkeld PG, Wheeler WJ, Yi P, Zmijewski M (2004) Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett 14(13):3481\u20133486. https:\/\/doi.org\/10.1016\/j.bmcl.2004.04.066. From NLM Medline","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"3_CR178","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/oby.2009.444","volume":"18","author":"KA Lantz","year":"2010","unstructured":"Lantz KA, Hart SG, Planey SL, Roitman MF, Ruiz-White IA, Wolfe HR, McLane MP (2010) Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice. Obesity (Silver Spring) 18(8):1516\u20131523. https:\/\/doi.org\/10.1038\/oby.2009.444. From NLM Medline","journal-title":"Obesity (Silver Spring)"},{"issue":"22","key":"3_CR179","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1016\/j.bmcl.2005.08.028","volume":"15","author":"GB Lapa","year":"2005","unstructured":"Lapa GB, Byrd GD, Lapa AA, Budygin EA, Childers SR, Jones SR, Harp JJ (2005) The synthesis and biological evaluation of dopamine transporter inhibiting activity of substituted diphenylmethoxypiperidines. Bioorg Med Chem Lett 15(22):4915\u20134918. https:\/\/doi.org\/10.1016\/j.bmcl.2005.08.028. From NLM Medline","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"3_CR180","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/0014-2999(89)90363-4","volume":"166","author":"PH Andersen","year":"1989","unstructured":"Andersen PH (1989) The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166(3):493\u2013504. https:\/\/doi.org\/10.1016\/0014-2999(89)90363-4. From NLM Medline","journal-title":"Eur J Pharmacol"},{"issue":"16","key":"3_CR181","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/s0960-894x(02)00348-7","volume":"12","author":"S Ananthan","year":"2002","unstructured":"Ananthan S, Saini SK, Khare R, Clayton SD, Dersch CM, Rothman RB (2002) Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett 12(16):2225\u20132228. https:\/\/doi.org\/10.1016\/s0960-894x(02)00348-7. From NLM Medline","journal-title":"Bioorg Med Chem Lett"},{"key":"3_CR182","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2210-6-6","volume":"6","author":"DD Han","year":"2006","unstructured":"Han DD, Gu HH (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6:6. https:\/\/doi.org\/10.1186\/1471-2210-6-6. From NLM Medline","journal-title":"BMC Pharmacol"},{"key":"3_CR183","doi-asserted-by":"publisher","first-page":"31385","DOI":"10.1038\/srep31385","volume":"6","author":"E Solis Jr","year":"2016","unstructured":"Solis E Jr, Suyama JA, Lazenka MF, DeFelice LJ, Negus SS, Blough BE, Banks ML (2016) Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters. Sci Rep 6:31385. https:\/\/doi.org\/10.1038\/srep31385. From NLM Medline","journal-title":"Sci Rep"},{"issue":"9","key":"3_CR184","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1021\/ml500187a","volume":"5","author":"M Han","year":"2014","unstructured":"Han M, Song C, Jeong N, Hahn HG (2014) Exploration of 3-Aminoazetidines as triple reuptake inhibitors by bioisosteric modification of 3-alpha-Oxyazetidine. ACS Med Chem Lett 5(9):999\u20131004. https:\/\/doi.org\/10.1021\/ml500187a. From NLM PubMed-not-MEDLINE","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"3_CR185","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","volume":"39","author":"RB Rothman","year":"2001","unstructured":"Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39(1):32\u201341. https:\/\/doi.org\/10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. From NLM Medline","journal-title":"Synapse"},{"issue":"1","key":"3_CR186","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1124\/jpet.103.053975","volume":"307","author":"RB Rothman","year":"2003","unstructured":"Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA (2003) In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307(1):138\u2013145. https:\/\/doi.org\/10.1124\/jpet.103.053975. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"15","key":"3_CR187","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1021\/jm9706729","volume":"42","author":"FI Carroll","year":"1999","unstructured":"Carroll FI, Howell LL, Kuhar MJ (1999) Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 42(15):2721\u20132736. https:\/\/doi.org\/10.1021\/jm9706729. From NLM Medline","journal-title":"J Med Chem"},{"issue":"8","key":"3_CR188","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28(8):1400\u20131411. https:\/\/doi.org\/10.1038\/sj.npp.1300203. From NLM Medline","journal-title":"Neuropsychopharmacology"},{"issue":"23","key":"3_CR189","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1021\/jm980156y","volume":"41","author":"SM Efange","year":"1998","unstructured":"Efange SM, Mash DC, Khare AB, Ouyang Q (1998) Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes. J Med Chem 41(23):4486\u20134491. https:\/\/doi.org\/10.1021\/jm980156y. From NLM Medline","journal-title":"J Med Chem"},{"issue":"2","key":"3_CR190","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1124\/jpet.106.106583","volume":"319","author":"BK Madras","year":"2006","unstructured":"Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, Johnson R, Livni E, Spencer TJ, Bonab AA et al (2006) Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319(2):561\u2013569. https:\/\/doi.org\/10.1124\/jpet.106.106583. From NLM Medline","journal-title":"J Pharmacol Exp Ther"},{"issue":"16","key":"3_CR191","doi-asserted-by":"publisher","first-page":"6112","DOI":"10.1021\/jm1005034","volume":"53","author":"P Zhang","year":"2010","unstructured":"Zhang P, Cyriac G, Kopajtic T, Zhao Y, Javitch JA, Katz JL, Newman AH (2010) Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters. J Med Chem 53(16):6112\u20136121. https:\/\/doi.org\/10.1021\/jm1005034. From NLM Medline","journal-title":"J Med Chem"}],"container-title":["Advances in Neurobiology","Monoamine Transporters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-96364-3_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:59:54Z","timestamp":1776794394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-96364-3_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031963636","9783031963643"],"references-count":191,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-96364-3_3","relation":{},"ISSN":["2190-5215","2190-5223"],"issn-type":[{"value":"2190-5215","type":"print"},{"value":"2190-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"7 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}